Skip to content
Peptide research

CNP

Also known as C-type Natriuretic Peptide
Category
Cardiovascular
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A natural vasodilating peptide marketed for cardiovascular and anti-aging support, though its strongest evidence is a long-acting analog's pediatric growth benefit for achondroplasia, not adult use. That effect is solid. Small human infusion experiments demonstrate vascular effects, but clinical cardiovascular benefit remains unproven. Main risks are injection-site reactions and transient blood-pressure drops. The pediatric analog is FDA-approved; native CNP is not, and unregulated products sold online carry no quality assurance.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Increased annualized growth velocity by ~1.57 cm/year in children with achondroplasia

    High

    Confirmed in a randomized, placebo-controlled phase 3 trial of 121 children over 52 weeks.

  • Sustained growth improvement over 7 years of treatment in extension studies

    Medium

    Open-label extension studies show sustained growth benefit through 7 years, without a randomized comparator.

  • Improved body proportions (upper-to-lower segment ratio) with continued treatment

    Medium

    Extension studies report improved body proportions versus historical controls, not a randomized comparison.

Evidence limits

Evidence Level
Strong Evidence (FDA-Approved Drug)

Vosoritide (Voxzogo) is backed by Phase 2 and Phase 3 randomized controlled trials, long-term extension studies out to 7 years, and real-world confirmation from multiple countries. The Phase 3 trial (n=121) met its primary endpoint with a statistically significant increase in growth velocity. FDA approved November 2021; EMA approved August 2021. Additional regulatory approvals in Japan, Australia, and other countries.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    Not recommended for children outside an approved pediatric indication (vosoritide is approved for children with achondroplasia).

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Injection site reactions

    High
  • Transient hypotension (temporary blood pressure drop)

    Moderate
  • Vomiting and gastrointestinal symptoms

    Low
  • Serious adverse events (rare)

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.